Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae

Laura Pagani, Roberta Migliavacca, Francesco Luzzaro, Ernesto Giacobone, Mariagrazia Perilli, Piero Micheletti, Gianfranco Amicosante

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

β-Lactam resistance on the part of the Enterobacteriaceae causes serious therapeutic problems in our institutions due to their production of extended-spectrum β-lactamases (ESβLs). We studied the in vitro activity of β-lactam/β-lactamase inhibitor combinations and third-generation cephalosporins and monobactams against 71 clinically relevant Enterobacteriaceae which produced TEM- and SHV-derivative ESβLs. Of the single drugs and combinations tested, piperacillin/tazobactam proved to be the most effective. Piperacillin/tazobactam was highly active against Proteus mirabilis, with minimum inhibitory concentrations (MICs) ranging from 0.125 to 16 μg/ml; Escherichia coli (MICs from 2 to 16 μg/ml) and Serratia marcescens (MICs from 4 to 8 μg/ml), while its activity against Klebsiella pneumoniae ESβL producers turned out to be closely related to the type and the amount of enzyme produced, the MIC ranging from 1 to 128 μg/ml. The antibacterial activity of piperacillin/tazobactam was stronger than that of ticarcillin/clavulanate, ceftriaxone, cefotaxime, ceftazidime and aztreonam, and the combination shared favorable in vitro activity properties against the ESβL producers with imipenem which, however, should be kept as reserve product.

Original languageEnglish
Pages (from-to)377-384
Number of pages8
JournalChemotherapy
Volume44
Issue number6
DOIs
Publication statusPublished - Nov 1998

Fingerprint

Microbial Sensitivity Tests
Enterobacteriaceae
Lactams
Monobactams
Ticarcillin
Aztreonam
Proteus mirabilis
Clavulanic Acid
Serratia marcescens
Ceftazidime
Cefotaxime
Ceftriaxone
Imipenem
Klebsiella pneumoniae
Cephalosporins
Escherichia coli
tazobactam drug combination piperacillin
Enzymes
In Vitro Techniques
Therapeutics

Keywords

  • β-Lactam/β-lactamase inhibitors
  • Aztreonam
  • Cefotaxime
  • Ceftazidime
  • Ceftriaxone
  • Enterobacteriaceae
  • Extended-spectrum β-lactamase
  • Piperacillin/tazobactam

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae. / Pagani, Laura; Migliavacca, Roberta; Luzzaro, Francesco; Giacobone, Ernesto; Perilli, Mariagrazia; Micheletti, Piero; Amicosante, Gianfranco.

In: Chemotherapy, Vol. 44, No. 6, 11.1998, p. 377-384.

Research output: Contribution to journalArticle

Pagani, Laura ; Migliavacca, Roberta ; Luzzaro, Francesco ; Giacobone, Ernesto ; Perilli, Mariagrazia ; Micheletti, Piero ; Amicosante, Gianfranco. / Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae. In: Chemotherapy. 1998 ; Vol. 44, No. 6. pp. 377-384.
@article{5b5abb77188143c58e1511a7930e3cbb,
title = "Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae",
abstract = "β-Lactam resistance on the part of the Enterobacteriaceae causes serious therapeutic problems in our institutions due to their production of extended-spectrum β-lactamases (ESβLs). We studied the in vitro activity of β-lactam/β-lactamase inhibitor combinations and third-generation cephalosporins and monobactams against 71 clinically relevant Enterobacteriaceae which produced TEM- and SHV-derivative ESβLs. Of the single drugs and combinations tested, piperacillin/tazobactam proved to be the most effective. Piperacillin/tazobactam was highly active against Proteus mirabilis, with minimum inhibitory concentrations (MICs) ranging from 0.125 to 16 μg/ml; Escherichia coli (MICs from 2 to 16 μg/ml) and Serratia marcescens (MICs from 4 to 8 μg/ml), while its activity against Klebsiella pneumoniae ESβL producers turned out to be closely related to the type and the amount of enzyme produced, the MIC ranging from 1 to 128 μg/ml. The antibacterial activity of piperacillin/tazobactam was stronger than that of ticarcillin/clavulanate, ceftriaxone, cefotaxime, ceftazidime and aztreonam, and the combination shared favorable in vitro activity properties against the ESβL producers with imipenem which, however, should be kept as reserve product.",
keywords = "β-Lactam/β-lactamase inhibitors, Aztreonam, Cefotaxime, Ceftazidime, Ceftriaxone, Enterobacteriaceae, Extended-spectrum β-lactamase, Piperacillin/tazobactam",
author = "Laura Pagani and Roberta Migliavacca and Francesco Luzzaro and Ernesto Giacobone and Mariagrazia Perilli and Piero Micheletti and Gianfranco Amicosante",
year = "1998",
month = "11",
doi = "10.1159/000007147",
language = "English",
volume = "44",
pages = "377--384",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum β-lactamase-producing enterobacteriaceae

AU - Pagani, Laura

AU - Migliavacca, Roberta

AU - Luzzaro, Francesco

AU - Giacobone, Ernesto

AU - Perilli, Mariagrazia

AU - Micheletti, Piero

AU - Amicosante, Gianfranco

PY - 1998/11

Y1 - 1998/11

N2 - β-Lactam resistance on the part of the Enterobacteriaceae causes serious therapeutic problems in our institutions due to their production of extended-spectrum β-lactamases (ESβLs). We studied the in vitro activity of β-lactam/β-lactamase inhibitor combinations and third-generation cephalosporins and monobactams against 71 clinically relevant Enterobacteriaceae which produced TEM- and SHV-derivative ESβLs. Of the single drugs and combinations tested, piperacillin/tazobactam proved to be the most effective. Piperacillin/tazobactam was highly active against Proteus mirabilis, with minimum inhibitory concentrations (MICs) ranging from 0.125 to 16 μg/ml; Escherichia coli (MICs from 2 to 16 μg/ml) and Serratia marcescens (MICs from 4 to 8 μg/ml), while its activity against Klebsiella pneumoniae ESβL producers turned out to be closely related to the type and the amount of enzyme produced, the MIC ranging from 1 to 128 μg/ml. The antibacterial activity of piperacillin/tazobactam was stronger than that of ticarcillin/clavulanate, ceftriaxone, cefotaxime, ceftazidime and aztreonam, and the combination shared favorable in vitro activity properties against the ESβL producers with imipenem which, however, should be kept as reserve product.

AB - β-Lactam resistance on the part of the Enterobacteriaceae causes serious therapeutic problems in our institutions due to their production of extended-spectrum β-lactamases (ESβLs). We studied the in vitro activity of β-lactam/β-lactamase inhibitor combinations and third-generation cephalosporins and monobactams against 71 clinically relevant Enterobacteriaceae which produced TEM- and SHV-derivative ESβLs. Of the single drugs and combinations tested, piperacillin/tazobactam proved to be the most effective. Piperacillin/tazobactam was highly active against Proteus mirabilis, with minimum inhibitory concentrations (MICs) ranging from 0.125 to 16 μg/ml; Escherichia coli (MICs from 2 to 16 μg/ml) and Serratia marcescens (MICs from 4 to 8 μg/ml), while its activity against Klebsiella pneumoniae ESβL producers turned out to be closely related to the type and the amount of enzyme produced, the MIC ranging from 1 to 128 μg/ml. The antibacterial activity of piperacillin/tazobactam was stronger than that of ticarcillin/clavulanate, ceftriaxone, cefotaxime, ceftazidime and aztreonam, and the combination shared favorable in vitro activity properties against the ESβL producers with imipenem which, however, should be kept as reserve product.

KW - β-Lactam/β-lactamase inhibitors

KW - Aztreonam

KW - Cefotaxime

KW - Ceftazidime

KW - Ceftriaxone

KW - Enterobacteriaceae

KW - Extended-spectrum β-lactamase

KW - Piperacillin/tazobactam

UR - http://www.scopus.com/inward/record.url?scp=0031671899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031671899&partnerID=8YFLogxK

U2 - 10.1159/000007147

DO - 10.1159/000007147

M3 - Article

C2 - 9755296

AN - SCOPUS:0031671899

VL - 44

SP - 377

EP - 384

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 6

ER -